133 related articles for article (PubMed ID: 36455483)
1. Design, synthesis, and metabolite identification of Tamoxifen esterase-activatable prodrugs.
Elbagoury RM; Shenouda MA; Elnakib HE; Wober J; Abadi AH; Ahmed NS
Bioorg Chem; 2023 Feb; 131():106303. PubMed ID: 36455483
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of novel tamoxifen analogues that avoid CYP2D6 metabolism.
Ahmed NS; Elghazawy NH; ElHady AK; Engel M; Hartmann RW; Abadi AH
Eur J Med Chem; 2016 Apr; 112():171-179. PubMed ID: 26896706
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of novel flexible tamoxifen analogues to overcome CYP2D6 polymorphism and their biological evaluation on MCF-7 cell line.
Ahmed NS; Wober J
Drug Dev Res; 2020 Jun; 81(4):444-455. PubMed ID: 31916635
[TBL] [Abstract][Full Text] [Related]
4. Flexible Etherified and Esterified Triphenylethylene Derivatives and Their Evaluation on ER-positive and Triple-Negative Breast Cancer Cell Lines.
Hassan AS; Wober J; Vollmer G; Abadi AH; Ahmed NS
ChemMedChem; 2022 Apr; 17(7):e202100720. PubMed ID: 35076180
[TBL] [Abstract][Full Text] [Related]
5. [Advances in the research of pharmacogenomics of tamoxifen].
Xiong W; Zhao JJ; Wang L; Jiang XH; Tao XQ
Yao Xue Xue Bao; 2016 Sep; 51(9):1356-67. PubMed ID: 29924509
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer.
Ishiguro H; Ohno S; Yamamoto Y; Takao S; Sato N; Fujisawa T; Kadoya T; Kuroi K; Bando H; Teramura Y; Iwata H; Tanaka S; Toi M
Breast Cancer; 2019 Sep; 26(5):535-543. PubMed ID: 30734152
[TBL] [Abstract][Full Text] [Related]
7. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
[TBL] [Abstract][Full Text] [Related]
8. Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites.
Wolf DM; Langan-Fahey SM; Parker CJ; McCague R; Jordan VC
J Natl Cancer Inst; 1993 May; 85(10):806-12. PubMed ID: 8487325
[TBL] [Abstract][Full Text] [Related]
9. Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy.
Antunes MV; Linden R; Santos TV; Wallemacq P; Haufroid V; Classen JF; Andreolla H; Costa N; Fontanive TO; Rosa DD
Ther Drug Monit; 2012 Aug; 34(4):422-31. PubMed ID: 22777153
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.
Maximov PY; McDaniel RE; Fernandes DJ; Bhatta P; Korostyshevskiy VR; Curpan RF; Jordan VC
J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25258390
[TBL] [Abstract][Full Text] [Related]
11. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score.
Barginear MF; Jaremko M; Peter I; Yu C; Kasai Y; Kemeny M; Raptis G; Desnick RJ
Clin Pharmacol Ther; 2011 Oct; 90(4):605-11. PubMed ID: 21900890
[TBL] [Abstract][Full Text] [Related]
12. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.
Dehal SS; Kupfer D
Cancer Res; 1997 Aug; 57(16):3402-6. PubMed ID: 9270005
[TBL] [Abstract][Full Text] [Related]
13. Role and pharmacologic significance of cytochrome P-450 2D6 in oxidative metabolism of toremifene and tamoxifen.
Kim J; Coss CC; Barrett CM; Mohler ML; Bohl CE; Li CM; He Y; Veverka KA; Dalton JT
Int J Cancer; 2013 Mar; 132(6):1475-85. PubMed ID: 22915089
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of novel flexible ester-containing analogs of tamoxifen and their evaluation as anticancer agents.
Elghazawy NH; Engel M; Hartmann RW; Hamed MM; Ahmed NS; Abadi AH
Future Med Chem; 2016; 8(3):249-56. PubMed ID: 26898104
[TBL] [Abstract][Full Text] [Related]
15. Elimination of antiestrogenic effects of active tamoxifen metabolites by glucuronidation.
Zheng Y; Sun D; Sharma AK; Chen G; Amin S; Lazarus P
Drug Metab Dispos; 2007 Oct; 35(10):1942-8. PubMed ID: 17620345
[TBL] [Abstract][Full Text] [Related]
16. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
Schroth W; Goetz MP; Hamann U; Fasching PA; Schmidt M; Winter S; Fritz P; Simon W; Suman VJ; Ames MM; Safgren SL; Kuffel MJ; Ulmer HU; Boländer J; Strick R; Beckmann MW; Koelbl H; Weinshilboum RM; Ingle JN; Eichelbaum M; Schwab M; Brauch H
JAMA; 2009 Oct; 302(13):1429-36. PubMed ID: 19809024
[TBL] [Abstract][Full Text] [Related]
17. Manipulating Estrogenic/Anti-Estrogenic Activity of Triphenylethylenes towards Development of Novel Anti-Neoplastic SERMs.
Elnakib HE; Ramsis MM; Albably NO; Vector MA; Weigand JJ; Schwedtmann K; Wober J; Zierau O; Vollmer G; Abadi AH; Ahmed NS
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830456
[TBL] [Abstract][Full Text] [Related]
18. Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.
Ximenez JPB; de Andrade JM; Marques MP; Coelho EB; Suarez-Kurtz G; Lanchote VL
BMC Pharmacol Toxicol; 2019 Dec; 20(Suppl 1):81. PubMed ID: 31852530
[TBL] [Abstract][Full Text] [Related]
19. [CYP2D6 polymorphisms and tamoxifen: therapeutic perspectives in the management of hormonodependent breast cancer patients].
Barrière J; Formento JL; Milano G; Ferrero JM
Bull Cancer; 2010 Mar; 97(3):311-20. PubMed ID: 20123649
[TBL] [Abstract][Full Text] [Related]
20. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.
Lim YC; Desta Z; Flockhart DA; Skaar TC
Cancer Chemother Pharmacol; 2005 May; 55(5):471-8. PubMed ID: 15685451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
